Claims
- 1. A pharmaceutical composition comprising an anti-Ly-9 antibody specific for Ly-9 expressing cells of a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, wherein said antibody specifically binds to a polypeptide having an amino acid sequence of SEQ ID. NO: 2.
- 2. The pharmaceutical composition of claim 1, wherein said antibody is a monoclonal anti-Ly-9 antibody or fragment thereof.
- 3. The pharmaceutical composition of claim 1, wherein said antibody is administered in an amount effective to kill or inhibit the growth of cells of a disease selected from the group consisting a lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, wherein said antibody specifically binds to a polypeptide having an amino acid sequence of SEQ ID. NO: 2.
- 4. A method of targeting Ly-9 protein on cells of a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to target said Ly-9-expressing cells, wherein said composition is an anti-Ly-9 antibody that specifically binds to a polypeptide having an amino acid sequence of SEQ ID NO: 2.
- 5. A method of killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of a T or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition is an anti-Ly-9 antibody that specifically binds to a polypeptide having an amino acid sequence of SEQ ID. NO: 2.
- 6. A method of killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of a T- or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a vaccine to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said vaccine comprises a Ly-9 polypeptide having an amino acid sequence of SEQ ID NO:2.
- 7. A method of killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of a T or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition comprises a nucleic acid of SEQ ID NO: 1 encoding Ly-9, within a recombinant vector.
- 8. A method of killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of a T or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the step of administering a composition to said cells in an amount effective to kill or inhibit the growth of said cells, wherein said composition comprises an antigen-presenting cell comprising a nucleic acid of SEQ ID NO: 1, encoding Ly-9, within a recombinant vector.
- 9. The method according to claims 4, 5, 6, 7, or 8, wherein said cells are contacted with as second therapeutic agent.
- 10. The method according to claim 4 or 5, wherein said anti-Ly-9 antibody composition is administered in an amount effective to achieve a dosage range from about 0.1 to about 10 mg/kg body weight.
- 11. The method according to claims 4, 5, 6, 7, or 8, wherein said pharmaceutical composition is administered in a sterile preparation together with a pharmaceutically acceptable carrier therefore.
- 12. A method of diagnosing a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, comprising the steps of:
(a) detecting or measuring the expression of Ly-9 protein on a cell; and (b) comparing said expression to a standard indicative of said disease.
- 13. The method according to claim 12, wherein said expression is Ly-9 mRNA expression.
- 14. The method according to claim 12, wherein said expression is detected or measured using anti-Ly-9 antibodies.
- 15. Use of an anti-Ly-9 antibody in preparation of a medicament for killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs, wherein said antibody specifically binds to a polypeptide having the amino acid sequence of SEQ ID NO:2.
- 16. Use of a polypeptide having an amino acid sequence of SEQ ID NO:2 in preparation of a vaccine for killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chrinic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs.
- 17. Use of a nucleic acid of SEQ ID NO:1 encoding Ly-9 or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of Ly-9-expressing cells of a disease selected from the group consisting of a T or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs.
- 18. Use of an antigen-presenting cell comprising a nucleic acid of SEQ ID NO:1 encoding Ly-9 or immunogenic fragment thereof, within a recombinant vector, in preparation of a medicament for killing or inhibiting the growth of Ly-9-expressing cells that cause a disease selected from the group consisting of a T or B cell lymphoproliferative disorder selected from the group consisting of acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute lymphoma, lymphosarcoma cell leukemia, autoimmune disorder, and rejection of transplanted tissues or organs.
- 19. An antibody that specifically binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- 20. The antibody of claim 19, wherein said antibody is a monoclonal anti-Ly-9 antibody or fragment thereof.
- 21. The antibody of claim 19, wherein said antibody is labeled with a radioisotope.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of U.S. application Ser. No. 10/310,612 filed on Dec. 04, 2002, entitled “Methods of Therapy and Diagnosis Using Targeting of Cells That Express Ly-9,” Attorney Docket No. HYS-68. This and all other U.S. Patents and Patent Applications cited herein are hereby incorporated by reference in their entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10310612 |
Dec 2002 |
US |
Child |
10328538 |
Dec 2002 |
US |